Patents by Inventor James D. Rodgers

James D. Rodgers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210253584
    Abstract: The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.
    Type: Application
    Filed: February 16, 2021
    Publication date: August 19, 2021
    Inventors: Jiacheng Zhou, Pingli Liu, Qiyan Lin, Brian W. Metcalf, David Meloni, Yongchun Pan, Michael Xia, Mei Li, Tai-Yuen Yue, James D. Rodgers, Haisheng Wang
  • Patent number: 11091484
    Abstract: The present invention relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: August 17, 2021
    Assignee: Incyte Corporation
    Inventors: James D. Rodgers, Stacey Shepard, Haisheng Wang, Lixin Shao
  • Publication number: 20210188872
    Abstract: The present invention relates to tricyclic heterocycles of Formula (I): which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: December 11, 2020
    Publication date: June 24, 2021
    Inventors: Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, JR., James D. Rodgers
  • Patent number: 10975085
    Abstract: The present invention is related to processes for preparing a composition comprising (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile, and related synthetic intermediate compounds. This compound is useful as an inhibitor of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: April 13, 2021
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Jiacheng Zhou, James D. Rodgers, Haisheng Wang
  • Patent number: 10919912
    Abstract: The present invention relates to tricyclic heterocycles of Formula (I): which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: February 16, 2021
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, Jr., James D. Rodgers
  • Publication number: 20200338077
    Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Application
    Filed: March 17, 2020
    Publication date: October 29, 2020
    Inventors: James D. Rodgers, Stacey Shepard
  • Publication number: 20200197401
    Abstract: The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Application
    Filed: March 2, 2020
    Publication date: June 25, 2020
    Inventors: Hui-Yin Li, James D. Rodgers
  • Patent number: 10639310
    Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: May 5, 2020
    Assignee: Incyte Corporation
    Inventors: James D. Rodgers, Stacey Shepard
  • Patent number: 10640506
    Abstract: The present invention provides cyclobutyl substituted pyrrolopyrimidines and pyrrolopyridines of Formula I: wherein X, Y, Z, L, A, R5, n and m are defined above, as well as their compositions and methods of use, that modulate the activity of Janus kinases (JAKs) and are useful in the treatment of diseases related to the activity of JAKs including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: May 5, 2020
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: James D. Rodgers, Stacey Shepard, Lixin Shao, Joseph Glenn
  • Publication number: 20200131195
    Abstract: The present invention relates to tricyclic heterocycles of Formula (I): which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: September 27, 2019
    Publication date: April 30, 2020
    Inventors: Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, JR., James D. Rodgers
  • Patent number: 10610530
    Abstract: The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: April 7, 2020
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Hui-Yin Li, James D. Rodgers
  • Publication number: 20200038404
    Abstract: The present invention provides active metablites of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Application
    Filed: September 26, 2019
    Publication date: February 6, 2020
    Inventors: James D. Rodgers, Argyrios G. Arvanitis, Jack Guoen Shi, Stacey Shepard
  • Publication number: 20200017497
    Abstract: The present invention relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: September 5, 2019
    Publication date: January 16, 2020
    Inventors: James D. Rodgers, Stacey Shepard, Haisheng Wang, Lixin Shao
  • Publication number: 20200002341
    Abstract: The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.
    Type: Application
    Filed: June 10, 2019
    Publication date: January 2, 2020
    Inventors: Jiacheng Zhou, James D. Rodgers, Haisheng Wang
  • Patent number: 10463667
    Abstract: The present invention provides active metabolites of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: November 5, 2019
    Assignees: INCYTE INCORPORATION, INCYTE HOLDINGS CORPORATION
    Inventors: James D. Rodgers, Argyrios G. Arvanitis, Jack Guoen Shi, Stacey Shepard
  • Patent number: 10464947
    Abstract: The present invention relates to tricyclic heterocycles of Formula (I): which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: November 5, 2019
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, Jr., James D. Rodgers
  • Patent number: 10442803
    Abstract: The present invention relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: October 15, 2019
    Assignee: Incyte Corporation
    Inventors: James D. Rodgers, Stacey Shepard, Haisheng Wang, Lixin Shao
  • Patent number: 10398699
    Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: September 3, 2019
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: James D. Rodgers, Stacey Shepard
  • Patent number: 10364248
    Abstract: The present invention is related to processes for preparing 4-chloro-7H-pyrollo[2,3,-d]pyrimidine, and related synthetic intermediate compounds. 4-Chloro-7H-pyrrolo[2,3,-d]pyrimidine is an intermediate for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines, which are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: July 30, 2019
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Jiacheng Zhou, James D. Rodgers, Haisheng Wang
  • Publication number: 20190135813
    Abstract: The present invention provides cyclobutyl substituted pyrrolopyrimidines and pyrrolopyridines of Formula I: wherein X, Y, Z, L, A, R5, n and m are defined above, as well as their compositions and methods of use, that modulate the activity of Janus kinases (JAKs) and are useful in the treatment of diseases related to the activity of JAKs including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Application
    Filed: July 27, 2018
    Publication date: May 9, 2019
    Inventors: James D. Rodgers, Stacey Shepard, Wenyu Zhu, Lixin Shao, Joseph Glenn